New Retina Radio
New Retina Radio

02.22.24

The State of Biosimilars: How We Got Here and What It Means for Practice

Two biosimilars are approved for use in retina by the US FDA—and more will be approved in the coming years. What exactly are biosimilars? What benefit might they provide? And how confident are retina specialist that biosimilars will deliver safe, high-quality care?  Moderator John Kitchens, MD, sits down with retina specialists Carl Awh, MD, and Firas Rahhal, MD, to answer these questions, and to ask whether the economic realities of biosimilars make them a good choice for modern retina practices.  This podcast is editorially independent, supported with advertising by Sandoz. 

View full description +

MORE EPISODES

11.25.25

Global Discussions in GA: Educating Patients and Encouraging Follow-Up

Anat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD

11.25.25

Global Discussions in GA: Referral Patterns and Fellow-Eye Monitoring

Anat Loewenstein, MD; Jordi Monés, MD, PhD; Sobha Sivaprasad, MD; and Giovanni Staurenghi, MD

11.21.25

Endophthalmitis Rates With and Without Antibiotic Prophylaxis

Sruthi Arepalli, MD; Jesse Sengillo, MD; and Alexis Warren, MD

11.17.25

The Nuts and Bolts of GA Therapy: Wrapping Up the Conversation

Charles Wykoff, MD, PhD; Sruthi Arepalli, MD; and Kenneth Fan, MD, MBA

11.13.25

AAO '25: GLP-1s and AMD, and Parity in Retina Care

Aleksandra Rachitskaya, MD; and Julia Haller, MD

11.10.25

Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE

Rahul Khurana, MD; and Arshad Khanani, MD, MA

11.06.25

AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease

Peter Kaiser, MD; and Michel Michaelides, MD

11.03.25

The Nuts and Bolts of GA Therapy: The Discussions Continue

Charles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD

Show More